Esperion Therapeutics/$ESPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Esperion Therapeutics
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Ticker
$ESPR
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
304
ISIN
US29664W1053
Website
ESPR Metrics
BasicAdvanced
$197M
-
-$0.81
0.75
-
Price and volume
Market cap
$197M
Beta
0.75
52-week high
$3.39
52-week low
$0.69
Average daily volume
4.2M
Financial strength
Current ratio
1.176
Quick ratio
0.723
Long term debt to equity
-112.45
Total debt to equity
-139.368
Interest coverage (TTM)
-0.62%
Profitability
EBITDA (TTM)
-39.925
Gross margin (TTM)
47.82%
Net profit margin (TTM)
-59.03%
Operating margin (TTM)
-15.40%
Revenue per employee (TTM)
$850,000
Management effectiveness
Return on assets (TTM)
-7.17%
Return on equity (TTM)
42.53%
Valuation
Price to revenue (TTM)
0.742
Price to book
-0.5
Price to tangible book (TTM)
-0.5
Price to free cash flow (TTM)
-1.92
Free cash flow yield (TTM)
-52.09%
Free cash flow per share (TTM)
-51.76%
Growth
Revenue change (TTM)
12.99%
Earnings per share change (TTM)
17.46%
3-year revenue growth (CAGR)
42.71%
3-year earnings per share growth (CAGR)
-49.33%
10-year earnings per share growth (CAGR)
-9.73%
What the Analysts think about ESPR
Analyst ratings (Buy, Hold, Sell) for Esperion Therapeutics stock.
ESPR Financial Performance
Revenues and expenses
ESPR Earnings Performance
Company profitability
ESPR News
AllArticlesVideos
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
GlobeNewsWire·2 months ago
Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference
GlobeNewsWire·2 months ago
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Esperion Therapeutics stock?
Esperion Therapeutics (ESPR) has a market cap of $197M as of June 30, 2025.
What is the P/E ratio for Esperion Therapeutics stock?
The price to earnings (P/E) ratio for Esperion Therapeutics (ESPR) stock is 0 as of June 30, 2025.
Does Esperion Therapeutics stock pay dividends?
No, Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Esperion Therapeutics dividend payment date?
Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Esperion Therapeutics?
Esperion Therapeutics (ESPR) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.